Aspirin® protect 100 mg Magensaftresistente Tablette Acetylsalicylsäure
Sponsors
Weill Medical College Of Cornell University, University College London, Centre Hospitalier Universitaire Rouen, Assistance Publique Hopitaux De Paris
Conditions
Breast cancerColorectal adenomasLynch syndromeResected colon cancer with PI3K mutation stage III or II high riskcolon cancercoronary artery diseaseoesophageal cancerprostate cancer
Phase 3
Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.
Not yet recruitingCTIS2024-511306-23-00
Target: 204Updated: 2025-06-24
French prospective randomised double blind study on aspirin versus placebo in resected colon cancer with PI3K mutation stage III or II high risk (PRODIGE 50 - ASPIK)
Not yet recruitingCTIS2024-516007-16-00
Target: 264Updated: 2024-09-25
The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN)
RecruitingCTIS2023-506613-22-00
Start: 2024-09-25Target: 300Updated: 2026-01-19
AAS-Lynch - Assessment of the effect of a daily chemoprevention by aspirin low-dose of new or recurrent colorectal adenomas in patients with Lynch syndrome
Active, not recruitingCTIS2024-516601-23-00
Start: 2017-11-14Target: 852Updated: 2025-03-13